Recent Security Class Actions

Puma Biotechnology Inc (NYSE: PBYI)

Company Name:Puma Biotechnology Inc
Stock Symbol:NYSE: PBYI
Class Period Start:07/22/2014
Class Period End (inclusive):05/29/2015
Filing Deadline:08/02/2015

According to the law firm press release, Puma is a development stage biopharmaceutical company, focusing on the acquisition, development, and commercialization of products to enhance cancer care. The Company’s lead product candidate is an investigational drug known as PB272 (“neratinib”), which the Company had touted as an extended adjuvant treatment of human epidermal growth factor receptor 2 (“HER2”)-positive metastatic breast cancer.